MRG004A Antibody
Based on 1 Customer Validation
MRG004A Antibody (HuSC1-39) is a monoclonal antibody inhibitor targeting tissue factor (TF). MRG004A Antibody can be used to synthesize the antibody-drug conjugate (ADC) MRG004A. MRG004A Antibody can be used to research related to cancer.
For research use only. We do not sell to patients.
- Purity : 95.44%
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Species Reactivity
Human
In Vitro
MRG004A Antibody activates the STING pathway via proteasome-dependent degradation of TREX1, leading to cytosolic micronuclei accumulation, increased STING pathway phosphorylation, and STING-dependent induction of CCL5 and CXCL10 mRNA in HPAF-II, BxPC3, MDA-231, and HCC1806 cells[1].
MRG004A Antibody (15 μg/mL; 24 h for cytokine secretion, 48 h for viability) increases CXCL10 and IFN?γ secretion and reduces tumor cell viability in HPAF-II, BxPC3, or MDA-231 cells co-cultured with PBMCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human PDAC HPAF-II, BxPC3 cells, human TNBC MDA-231 cells, PBMCs
-
Concentration:15 μg/mL (cytokine secretion); 15 μg/mL (tumor cell viability)
-
Incubation Time:24 h (cytokine secretion); 48 h (tumor cell viability)
-
Result:Increased secretion of CXCL10 and IFN-γ.
Reduced tumor cell viability.
In Vivo
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous BxPC3 pancreatic ductal adenocarcinoma growth in nude mice, activates the STING innate immune pathway, reduces pro-tumor signaling, and depletes TREX1 protein levels[1].
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous HPAF-II pancreatic ductal adenocarcinoma growth in nude mice, activates the STING innate immune pathway, reduces pro-tumor signaling, and depletes TREX1 protein levels[1].
MRG004A Antibody (10 mg/kg; i.v.) inhibits subcutaneous HCC1806 triple-negative breast cancer growth in nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.v.
-
Result:Inhibited tumor growth.
Reduced TF, P-ERK, and P-AKT relative intensity in tumor sections.
Increased P-STING and P-TBK1 relative intensity in tumor sections.
Nearly eliminated TREX1 protein staining in tumor tissue.\nInhibited tumor growth.
Reduced TF, P-ERK, and P-AKT relative intensity in tumor sections.
Increased P-STING and P-TBK1 relative intensity in tumor sections.
Nearly eliminated TREX1 protein staining in tumor tissue.
-
Animal Model:Nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.v.
-
Result:Inhibited tumor growth.
Gene ID
Accession
Target
F3/Factor III/Tissue Factor/CD142
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Tissue Factor-hFc can bind MRG004A Antibody. The EC50 for this effect is 102.6 ng/mL.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[MRG004A Antibody]
-
Synonyms
HuSC1-39
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)